Retrospective Analysis of Clinical Factors Associated with a Greater Benefit with Axitinib in Metastatic Renal Cancer
Phase of Trial: Phase IV
Latest Information Update: 06 May 2019
Price : $35 *
At a glance
- Drugs Axitinib (Primary)
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- Acronyms AXILONG
- Sponsors Pfizer
- 01 May 2019 Status changed from active, no longer recruiting to completed.
- 22 Mar 2019 Status changed from recruiting to active, no longer recruiting.
- 09 Oct 2018 Planned End Date changed from 30 Sep 2018 to 30 Jun 2019.